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Abstract
BACKGROUND & AIMS—Specific neuronal circuits modulate autonomic outflow to liver and
white adipose tissue. Melanin-concentrating hormone (MCH)-deficient mice are hypophagic, lean,
and do not develop hepatosteatosis when fed a high-fat diet. Herein, we sought to investigate the
role of MCH, an orexigenic neuropeptide specifically expressed in the lateral hypothalamic area,
on hepatic and adipocyte metabolism.
METHODS—Chronic central administration of MCH and adenoviral vectors increasing MCH
signaling were performed in rats and mice. Vagal denervation was performed to assess its effect
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on liver metabolism. The peripheral effects on lipid metabolism were assessed by real-time
polymerase chain reaction and Western blot.
RESULTS—We showed that the activation of MCH receptors promotes nonalcoholic fatty liver
disease through the parasympathetic nervous system, whereas it increases fat deposition in white
adipose tissue via the suppression of sympathetic traffic. These metabolic actions are independent
of parallel changes in food intake and energy expenditure. In the liver, MCH triggers lipid
accumulation and lipid uptake, with c-Jun N-terminal kinase being an essential player, whereas in
adipocytes MCH induces metabolic pathways that promote lipid storage and decreases lipid
mobilization. Genetic activation of MCH receptors or infusion of MCH specifically in the lateral
hypothalamic area modulated hepatic lipid metabolism, whereas the specific activation of this
receptor in the arcuate nucleus affected adipocyte metabolism.
CONCLUSIONS—Our findings show that central MCH directly controls hepatic and adipocyte
metabolism through different pathways.
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Melanin-concentrating hormone (MCH) is a 19-aa neuropeptide selectively expressed in the
lateral hypothalamic area (LHA)1 with important effects on energy balance.2 Central
injections of MCH induce feeding in rodents, and its gene expression is increased after
fasting and leptin deficiency.2 MCH-induced food intake can be abolished by the co-
administration of α-melanocyte stimulating hormone,3,4 glucagon-like peptide,4 and
antagonists of the neuropeptide Y1 receptor.5
MCH knockout mice are hypophagic and lean when fed a normal diet,4 resistant to aging-
associated insulin resistance,6 resistant to diet-induced obesity,7 and do not develop
hepatosteatosis when fed with fat-enriched diets.8 Mice that overexpress MCH are obese and
hyperleptinemic.9 Furthermore, the lack of MCH attenuates leptin deficiency–induced
obesity in ob/ob mice.10,11
Specific central nervous system (CNS) regions modulate autonomic outflow to white
adipose tissue (WAT) and liver, controlling peripheral energy homeostasis.12 Particularly
within the hypothalamus, several nuclei can control hepatic and adipose metabolism. The
paraventricular hypothalamic nucleus of the hypothalamus innervates both tissues, with the
LHA and the arcuate nucleus of the hypothalamus (ARC) being upstream of the
paraventricular hypothalamic nucleus of the hypothalamus in this pathway. Leptin,13
insulin,14,15 ghrelin,16 neuropeptide Y,17 melanocortins,18 and glucagon-like peptide-119
directly control liver and/or WAT metabolism, and most of those signals require an intact
sympathetic nervous system (SNS) to exert their functions. At the hypothalamic level, these
molecules act primarily on the neurons located in the ARC. However, the functional role
and neural pathways of the LHA20,21 mediating the CNS control of peripheral metabolism
have been poorly studied. Here, we show that central MCH actions on hepatic lipid
metabolism are controlled by the parasympathetic nervous system, whereas adipocyte
metabolism is mediated by the SNS. Although some extrahypothalamic areas expressing
MCH-immunoreactive fibers or MCH receptors (MCH-R) also might be involved in these
actions, we describe 2 different hypothalamic areas mediating the central effects of MCH on
peripheral metabolism, namely the ARC, which is essential for the control of WAT
metabolism, and the LHA modulating liver metabolism.
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Material and Methods
Animals and Surgery
For all experiments, 8- to 10-week-old (250–300 g) male Sprague–Dawley rats were used
(see the Supplementary Materials and Methods section).
Energy Expenditure, Locomotor Activity, Respiratory Quotient, and Lipid Use
These parameters were analyzed using a cage calorimetry system (LabMaster; TSE Systems,
Thuringia, Germany)19 (see the Supplementary Materials and Methods section).
Quantitative Reverse-Transcription Polymerase Chain Reaction Procedure
RNA was extracted using TRIzol reagent (Invitrogen, Paisley, UK) according to the
manufacturer’s instructions and as previously described.19 Primer sequences are described
in Supplementary Table 1.
Western Blot Analysis
Western blot was performed as previously described19 (see the Supplementary Materials and
Methods section).
Immunohistochemistry
Immunohistochemistry/immunofluorescence approaches were performed to detect MCH-R,
Cellular FBJ osteosarcoma oncogene, phospho-extracellular-signal-regulated kinase, and
green fluorescence protein (see the Supplementary Materials and Methods section).
Tissue Triglycerides and Free Fatty Acid Content in WAT, Liver, and Feces
The extraction procedure for tissue triglycerides (TG) and free fatty acids (FFA) was
adapted from methods described previously19 (see the Supplementary Materials and
Methods section).
Sympathetic Nerve Activity Recording
Sympathetic nerve activity (SNA) recording was performed as previously described18 (see
the Supplementary Materials and Methods section).
Enzymatic Activity Assays
Fatty acid synthase (FAS) and lipoprotein lipase (LPL) activities were measured as
previously described18 (see the Supplementary Materials and Methods section).
Lipolysis In Vivo
Lipolysis was assessed as previously reported22 (see the Supplementary Materials and
Methods section).
Levels of Serum Metabolites and Hormones
Serum glucose and TG levels (Glucose and Triglyceride Spinreact, Girona, Spain), and FFA
levels (Wako, Richmond, VA) were assessed using a commercial kit based on a colorimetric
method. Serum insulin levels were measured by radioimmunoassay and serum
corticosterone levels were measured using a corticosterone enzyme-linked immunosorbent
assay kit (Enzo Life Sciences, Farmingdale, NY) following the manufacturer’s instructions.
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Oil Red Staining
Frozen sections of the livers (8 µm) were cut and stained in filtered Oil Red O for 10
minutes. Sections were washed in distilled water and counterstained with Mayers
hematoxylin for 3 minutes. Sections were mounted in aqueous mountant (glycerin jelly).
Stereotaxic Microinjection of Adenoviral Expression Vectors
Sprague–Dawley rats were placed in a stereotaxic frame and adenoviral vectors
overexpressing MCH-R were injected (see the Supplementary Materials and Methods
section).
Statistics
Results are shown as mean ± standard error of the mean. Statistical analysis was performed
using 1-way analysis of variance followed by a post hoc multiple comparison test
(Bonferroni test). A P value less than .05 was considered statistically significant.
Results
The CNS-MCH System Controls Adiposity Independent of Food Intake
Central infusion of MCH increased food intake in ad libitum–fed rats (MCH-ad lib) (Figure
1 A). A second control group of intracerebroventricular (ICV) MCH–infused animals was
pair-fed to match the intake of saline-infused controls (MCH-pf). Weight gain (Figure 1 B),
metabolic efficiency (Figure 1 C), and fat mass gain (Figure 1 D) of ICV MCH-ad lib and
MCH-pf rats was significantly higher than that of controls. Non–fat mass was increased
significantly after central infusion of MCH only in rats fed ad libitum (Figure 1 E). We did
not find any alteration in total energy expenditure or spontaneous locomotor activity
(Supplementary Figure 1 A–E). The expression of uncoupling protein-1, peroxisome
proliferator-activated receptor γ  co-activator-1-α , and peroxisome proliferator-activated α
receptor remained unchanged in the brown adipose tissue after central MCH treatment
(Supplementary Figure 2). However, central administration of MCH significantly increased
the respiratory quotient (RQ) (Figure 1 F and Supplemental Figure 1 F and G). Chronic
central MCH administration did not change serum levels of glucose, insulin, TG, or
cholesterol, but decreased levels of FFAs and corticosterone (Supplementary Table 2).
Central MCH Infusion Controls WAT Lipid Metabolism
The weight of specific fat depots was increased in MCH-treated groups (Figure 2 A).
Isoproterenol-stimulated lipolysis markedly increased FFA concentrations in serum in both
vehicle and MCH-treated rats (Figure 2 B). However, after 30 and 60 minutes of
isoproterenol injection, the levels of FFA in MCH-ad lib and MCH-pf rats were lower than
in control rats (Figure 2 B), suggesting that CNS MCH reduces the lipolytic rate. The size of
the adipocytes seemed slightly increased in ICV MCH-treated rats in comparison with
controls (Figure 2 C). Independently of hyperphagia, ICV MCH markedly augmented the
gene expression of key enzymes involved in lipid metabolism including acetyl-CoA
carboxylase α  (ACCα), FAS, and LPL (Supplementary Figure 3). At the post-
transcriptional level, ACCα  levels were increased significantly after central infusion of
MCH independently of food intake (Figure 2 E), whereas FAS protein levels and enzymatic
activity were higher only in ICV MCH-ad lib–treated rats (Figure 2 D and E), with no
changes in LPL, carnitine palmitoytransferase 1, uncoupling protein-1, or peroxisome
proliferator-activated receptor γ  co-activator-1-α  (Figure 2 E). Phospho hormone-sensitive
lipase (pHSL) and the ratio of pHSL/HSL was decreased in the WAT of MCH-treated rats
(Figure 2 E). Because the observed changes in the protein levels of enzymes promoting lipid
storage cannot entirely explain the food intake–independent increase in fat mass induced by
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CNS MCH, we investigated an alternative mechanism. We found that cell death-inducing
DNA fragmentation factor alpha-like effector A (CIDEA) protein levels were increased after
CNS-MCH stimulation, indicating a lower lipid oxidation (Figure 2 F).23 CIDEA expression
is regulated negatively via the mitogen-activated protein kinase c-Jun NH(2)-terminal kinase
1 (JNK1).23 Although total JNK1 was unchanged, phosphorylated JNK1 (pJNK1) and the
ratio of pJNK1/JNK1 was decreased (Figure 2 F).
Central MCH Infusion Controls Hepatic Lipid Metabolism
Central MCH infusion increased TG content (Figure 3 A) and decreased FFA levels (Figure
3 B) in the liver and serum in both MCH-ad lib and MCH-pf groups (Supplementary Figure
4). We failed to detect any changes at the transcriptional level (Figure 3 C). However, at the
protein level, phospho-AMP-activated protein kinase (pAMPK), pACC, and ACCα  were
decreased, whereas LPL was increased in centrally MCH-infused rats independent of
hyperphagia (Figure 3 D). Accordingly, the activity of LPL in the liver also was up-regulated
in both MCH-ad lib and MCH-pf groups (Figure 3 E). The expression of other enzymes
controlling high-density lipoprotein re-uptake (scavenger receptor class B type 1), the
endocytosis of cholesterol-rich low-density lipoprotein, and the hepatic lipoprotein assembly
and secretion, remained unchanged after chronic CNS MCH stimulation (Figure 3 C).
Accordingly, transcription factors modulating scavenger receptor class B type 1 expression
(farnesoid X receptor and liver receptor homolog 1) were not affected by MCH (Figure 3 C).
Hepatic JNK1 is involved in steatosis,24 and we found that the hepatic levels of total JNK1
were decreased after CNS MCH activation (Figure 3 F), whereas phosphorylated JNK1 was
increased (Figure 3 F), leading to an increased ratio of pJNK1/JNK1 (Figure 3 F).
Next, we assessed if CNS MCH also was affecting the lipid absorption. Although the fecal
output was unchanged (Supplementary Figure 5 A), the content of TG in the feces of both
MCH-ad lib and MCH-pf groups was lower than in the controls (Supplementary Figure 5 B),
suggesting that CNS MCH increases lipid absorption.
Peripheral MCH Administration Does Not Affect Either Liver or WAT Lipogenic Program
To rule out the possibility that centrally infused MCH leaks out of the CNS into the
circulation and elicits a response by directly acting at the peripheral level, we chronically
administered MCH peripherally. At the same doses as those infused centrally, MCH did not
change cumulative food intake (Supplementary Figure 6 A), body weight gain
(Supplementary Figure 6 B), WAT gene expression (Supplementary Figure 6 C), WAT
protein levels (Supplementary Figure 6 D and E), or hepatic protein levels (Supplementary
Figure 6 F and G). After subcutaneous infusion it is unlikely that MCH is 100% absorbed in
the plasma. Therefore, we performed a chronic intravenous infusion study with the same
amount, volume, and rate of infusion of MCH used for the ICV experiment. These results
indicated that chronic intravenous infusion of MCH increased food intake (Supplementary
Figure 7 A) and body weight gain (Supplementary Figure 7 B) when rats were fed ad libitum.
However, chronic intravenous infusion of MCH failed to affect adipocyte (Supplementary
Figure 7 C) or hepatic metabolism (Supplementary Figure 7 D).
Role of the SNS in the Central MCH Control of Adipose Fatty Acid Metabolism
White adipocytes are connected with the CNS via the autonomic nervous system, in
particular the SNS.12 β-adrenergic receptors (β-ARs) represent a key link involved in the
regulation of adipocyte lipid metabolism by the SNS.12 We found that central MCH infusion
diminished the expression of the 3 receptors, the decrease in β3-AR was independent of
changes in food intake (Figure 4 A).
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To determine whether CNS action of MCH can modulate the efferent SNS subserving
WAT, we used multifiber recording to test the effect of CNS MCH activation on WAT
SNA. ICV injection of MCH decreased SNA recorded from nerve endings in epididymal
WAT (Figure 4 B and Supplementary Figure 8 A). ICV MCH-induced decrease in WAT
SNA is dose-dependent (Supplementary Figure 8 B). Transection of the WAT nerve distal to
the recording site (assessing efferent SNA) did not affect the WAT sympathetic response
evoked by ICV MCH (Supplementary Figure 8 C). In contrast, ICV MCH had no significant
effect on the afferent nerve activity, recorded after cutting the nerve proximal to the
recording site (Supplementary Figure 8 C).
Next, we treated triple (β1-AR, β2-AR, and β3-AR) adrenoceptor-deficient mice (TKO)
with ICV MCH. MCH stimulated cumulative food intake and body weight gain (Figure 4 C)
in wild-type (WT) mice, whereas TKO mice showed increased food intake, but body weight
gain did not increase significantly (Figure 4 C). Protein levels of ACCα  and FAS were
increased significantly in the WAT of WT mice (Figure 4 D), but they remained unchanged
in the WAT of TKO mice infused with MCH (Figure 4 E). Finally, hepatic TG content was
increased significantly in both WT and TKO mice infused with MCH (Figure 4 F).
Role of the Vagus Nerve in the Central MCH Control of Hepatic Lipid Metabolism
We sought to determine whether the effect of central MCH on hepatic lipid metabolism
involved vagal innervation. The ICV MCH infusion was performed before the dissections of
dorsal and ventral branches of the vagus nerve. The effectiveness of this approach was
validated by assessing the expected morphologic changes in the stomach (Supplementary
Figure 9 A). Central MCH infusion significantly increased cumulative food intake
(Supplementary Figure 9 B) and body weight gain (Supplementary Figure 9 C) in sham-
operated rats, but not in vagotomized (VGX) rats. Stimulation of the CNS MCH system
enhanced the hepatic TG content (Figure 5 A), and decreased serum FFA (Figure 5 B) and
hepatic FFA (Figure 5 C) in sham-operated rats, but failed to do so in VGX rats. Staining of
lipid droplets was increased in sham MCH-treated rats, but not in VGX MCH-treated
animals (Figure 5 D). The effects of MCH on hepatic pACC and LPL were blunted after
vagotomy (Figure 5 E). Similarly, the increased ratio of pJNK1/JNK1 in the liver of sham-
operated rats also was prevented by vagotomy (Figure 5 E). In keeping with LPL protein
levels, hepatic LPL activity was increased by MCH in SHAM, but not in VGX, rats (Figure
5 F). However, vagotomy did not blunt the effects of MCH on the protein levels studied in
WAT (Supplementary Figure 9 D).
Role of JNK on Central MCH Control of Peripheral Lipid Metabolism
MCH administration significantly stimulated food intake in both WT and JNK1-deficient
mice (Figure 6 A). However, chronic central infusion of MCH failed to increase body weight
in JNK1 knockout (KO) mice (Figure 6 B). Interestingly, CNS infusion of MCH decreased
serum levels of FFA in WT mice, but not in JNK1 KO mice (Figure 6 C). Central infusion of
MCH increased the protein levels of CIDEA in the WAT of JNK1 KO mice (Supplementary
Figure 10 A). In JNK1 KO mice central activation of MCH decreased the hepatic protein
levels of pAMPK and pACC, but failed to affect LPL (Figure 6 D).
We also blocked JNK pharmacologically by using the JNK inhibitor SP600125.25 When rats
were injected twice daily intraperitoneally with 0.5 mg SP600125 during 1 week the
orexigenic effect of MCH (Supplementary Figure 10 B) and the MCH-induced body weight
gain (Supplementary Figure 10 C) were abolished. The reduction of serum FFA levels
caused by MCH also was reversed by SP600125 (Figure 6 E). The pharmacologic blockade
of JNK decreased MCH-induced protein levels of CIDEA in WAT (Supplementary Figure
10 D). In the liver, the up-regulation of LPL in MCH-treated rats also was blunted by the
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JNK inhibitor (Figure 6 F), whereas the protein levels of pAMPK, AMPKα1, and AMPKα2
were not affected by SP600125 (Figure 6 F).
MCH-R in the ARC and LHA Modulate Adipocyte and Hepatic Lipid Metabolism,
Respectively
The specific activation of MCH-R in the ARC (Figure 7 A) during 1 week increased body
weight gain and food intake (Figure 7 B). The adenoviral vectors overexpressing MCH-R
increased weight gain and food intake for 6 days (Supplementary Figure 11 A and B) and the
rate of success to reach the ARC was 62.5% (Supplementary Figure 12 A). In rats in which
the ARC was not reached there were no differences in food intake or body weight
(Supplementary Figure 13 A and B). MCH-R was co-localized with pERK in the ARC
(Supplementary Figure 14 A). The levels of C-FOS were up-regulated in the ARC of rats
injected with the adenoviral vector overexpressing MCH-R (Supplementary Figure 14 C).
When we analyzed protein levels in the liver, we found that the activation of MCH-R in the
ARC only increased pACC levels in the liver, with no changes in any of the other studied
proteins (Figure 7 C). However, in WAT we found a significant increase of ACCα  and FAS
and a decrease in pHSL and the pJNK/JNK ratio (Supplementary Figure 12 B). To
corroborate the results obtained with adenoviruses, we next used osmotic mini-pumps
connected to the ARC. We found that chronic infusion (1 week) of MCH directly into the
ARC increased body weight and food intake (Figure 7 B). The analysis of protein levels in
the liver failed to show any changes in any of the studied proteins (Figure 7 C). However,
after the infusion of MCH into the ARC we found increased levels of ACCα , CIDEA, and
FAS, and decreased levels of pJNK/JNK and pHSL in the WAT (Supplementary Figure
12 B).
Next, we assessed the effects of the specific activation of MCH-R in the LHA (Figure 7 D).
We found a significant increase in body weight gain and food intake (Figure 7 E). The
adenoviral vectors overexpressing MCH-R increased weight gain and food intake for 6 days
(Supplementary Figure 11 C and D) and the rate of success to reach the LHA was 87.5%
(Supplementary Figure 12 A). In rats in which the LHA was not reached there were no
differences in food intake or body weight (Supplementary Figure 13 C and D). MCH-R also
was co-localized with pERK in the LHA (Supplementary Figure 14 B). The levels of c-Fos
were up-regulated in the LHA of rats injected with the adenoviral vector overexpressing
MCH-R (Supplementary Figure 14 C). At the hepatic level, there was a down-regulation of
pACC, whereas LPL and the ratio of pJNK/JNK were augmented significantly (Figure 7 F).
In contrast, in WAT all the studied proteins remained unaltered after the activation of MCH-
R in the LHA (Supplementary Figure 12 C). To corroborate these results, we used osmotic
minipumps connected to the LHA. We found that chronic infusion (1 week) of MCH
directly into the LHA did not affect body weight or food intake (Figure 7 E). In the liver of
rats treated with MCH into the LHA we also found a decrease in pACC, and an increase in
LPL and pJNK/JNK levels (Figure 7 F), although we failed to detect any significant change
in the levels of the studied proteins in WAT (Supplementary Figure 12 C).
Finally, we investigated the potential role of the ventromedial hypothalamic nucleus of the
hypothalamus (VMH) mediating the central actions of MCH on energy balance
(Supplementary Figure 15 A). However, the specific activation of MCH-R in this nucleus did
not modify body weight gain, food intake, or protein levels in liver or WAT (Supplementary
Figure 15 B–E).
Discussion
We report here that the central MCH system directly controls peripheral lipid metabolism.
Specifically, we show that central infusion of MCH stimulates lipid absorption and lipid
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deposition in WAT and liver independently of its orexigenic action or changes in energy
expenditure. Our results suggest a molecular basis for a CNS MCH-induced switch in
nutrient partitioning and substrate use. Those actions likely occur through effects on 2
different pathways: the SNS mediates the effects of CNS MCH on adipocyte metabolism,
whereas the parasympathetic vagus nerve controls the effects of CNS MCH on hepatic
metabolism. Also, we show that both effects show a nucleus-specific pattern within the
hypothalamus. Thus, the specific activation of MCH-R in the ARC modulates adipocyte
metabolism, whereas when we triggered MCH-R in the LHA, marked changes were found
in hepatic metabolism.
Pharmacologic or genetic manipulation of MCH causes important alterations in feeding
behavior, body weight, and insulin resistance.2,4,6,9,10,26,27 In the current work, we
confirmed that chronic central infusion of MCH increases food intake and body weight gain,
and also stimulates lipid absorption and lipid deposition in WAT and liver. Interestingly,
those changes not only were independent of feeding behavior, but also of energy
expenditure, as shown in our indirect calorimetry data. The increased respiratory quotient
and the measured levels of lipogenic genes and proteins suggest that central MCH favors
lipid storage through changes in nutrient partitioning and substrate use. The increased WAT
and hepatic lipid deposition were mediated by tissue-specific molecular mechanisms.
MCH-treated rats had increased hepatic TG storage along with down-regulation of pAMPK
and pACC and specific up-regulation of hepatic activity of JNK1 and LPL.
Pharmacologic28,29 and genetic30–32 inhibition of JNK1 improves high-fat diet–induced
insulin resistance and inflammatory changes. Consistent with this, and in agreement with
our findings after CNS MCH stimulation, JNK activity was reported to be increased
abnormally in obesity.30 It is also important to point out that even though LPL is expressed
at low levels in the liver in normal conditions, it is increased markedly in morbidly obese
patients with nonalcoholic fatty liver disease.33 Our observations suggest that central MCH
stimulates hepatic TG storage and uptake. The parasympathetic vagus nerve appears to be a
crucial communication link mediating CNS control of hepatic metabolism.34,35 We
therefore tested the hypothesis that the vagus nerve may be responsible for mediating central
MCH actions on liver metabolism. When we investigated the specific effects of surgical
total vagotomy on hepatic lipid metabolism, the hepatic TG and FFA content in MCH-
treated VGX rats remained unchanged. The molecular targets mediating TG and FFA
content in the liver appear to be JNK1 and LPL because the up-regulation of these key
molecules modulating fatty acid metabolism after central MCH infusion in control rats was
blunted in MCH-treated VGX rats. These data show that the vagus nerve is mediating the
CNS MCH-induced regulation of hepatic lipid metabolism. To further evaluate the
relevance of JNK1 in the actions of the CNS-MCH system, we centrally infused MCH in
JNK1-deficient mice. We found that MCH failed to decrease serum FFA in mice lacking
JNK1, and this could be explained by the inability of MCH to up-regulate LPL in JNK1 KO
mice. In fact, it has been shown that a lack of JNK1 could affect the expression of LPL
induced by high-fat diet.36 Consistent with data obtained in genetically manipulated mice,
the pharmacologic blockade of JNK also blunted the CNS MCH-mediated actions on food
intake, body weight, serum FFA, and hepatic LPL protein levels. Therefore, JNK1 seems to
be an essential player in the modulation of central MCH actions on hepatic TG uptake, even
though it also is plausible to hypothesize that other isoforms of JNK might play a role in the
control of hepatic metabolism. Thus, 2 different mechanisms appear to modulate hepatic
lipid storage. On one hand, decreased levels of pAMPK are related to increased de novo
lipogenesis. On the other hand, the specific stimulation of JNK1 activity and LPL levels
indicate that the CNS-MCH stimulation triggers hepatic lipid uptake.
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The SNS connects WAT via a neuronal circuit with homeostatic control areas within the
hypothalamus and other brain areas.12,37 Combining electrophysiological studies and
genetically manipulated mice lacking β-ARs, we showed that central infusion of MCH
decreases the expression of β-ARs and the efferent SNA subserving in WAT. Consistently,
CNS-MCH stimulation failed to change body weight and WAT protein levels of lipogenic
enzymes in TKO mice, indicating that an intact SNS is necessary for central MCH actions
on body weight to occur. Within the WAT, this action seems to be modulated by 2
processes. First, CNS-MCH stimulation triggers lipid accumulation in WAT through an up-
regulation of ACCα  and FAS. However, this action partially is dependent on the orexigenic
role of MCH because FAS protein levels and activity were increased only in MCH-ad lib
rats. Those data suggested the involvement of a second pathway controlling the CNS MCH-
induced fat storage. We found that CIDEA, an enzyme strongly linked to the regulation of
fatty acid metabolism,38 was increased in the WAT after central ICV-MCH infusion.
According to previous studies in adipocytes,23 the activation of JNK1, a kinase that controls
cell development and function by regulation of transcription,39 blocks CIDEA. Thus, the
increased levels of CIDEA in WAT after CNS-MCH stimulation suggest a decrease in
lipolysis, a result that supports the decreased lipolysis found in MCH-treated rats in
comparison with vehicle rats.
We finally investigated the specific sites of action for MCH within the hypothalamus.
Indeed, MCH-ir fibers and MCH-R are distributed widely throughout the CNS1,40 and are
not restricted to the hypothalamus. Within the hypothalamus, MCH-R is located in the ARC,
LHA, and VMH,40 3 important nuclei modulating energy homeostasis. Our results show that
activation of MCH-R in both ARC and LHA increases body weight and food intake,
whereas the activation of MCH-R in the VMH had no effect. We also infused MCH directly
into the ARC and LHA during 1 week and confirmed that the chronic infusion of MCH
directly into the LHA controls hepatic lipid metabolism, whereas the chronic infusion of
MCH directly into the ARC controls adipocyte lipid metabolism. Overall, these findings
indicate that MCH-Rs in the ARC are needed for the control of adipocyte metabolism,
whereas MCH-Rs in the LHA are essential for hepatic metabolism. These results are in
agreement with previous reports showing that the ARC plays an important role in the control
of the SNS41,42 whereas the LHA interacts with the vagus nerve.43
In summary, we provide a combination of pharmacologic and genetic evidence to show that
the central MCH system increases lipid storage via direct modulation of hepatic and
adipocyte metabolism (Supplementary Figure 16). Overall, our findings reveal 2 novel
circuits linking MCH, a LHA-produced neuropeptide, with peripheral lipid metabolism, and
support the crucial concept that specific hypothalamic nuclei have independent autonomic
outflow pathways to individual metabolic organs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations used in this paper
ACCα acetyl-CoA carboxylase α
ARC arcuate nucleus of the hypothalamus
CIDEA cell death-inducing DNA fragmentation factor alpha-like effector A
CNS central nervous system
FAS fatty acid synthase
FFA free fatty acids
ICV intracerebroventricular
JNK1 c-Jun NH(2)-terminal kinase 1
LHA lateral hypothalamic area
LPL lipoprotein lipase
MCH melanin-concentrating hormone
MCH-ad lib ad libitum–fed melanin-concentrating hormone
MCH-pf pair fed melanin-concentrating hormone
MCH-R melanin-concentrating hormone receptor
pAMPK phospho-AMP-activated protein kinase
pHSL phospho hormone sensitive lipase
RQ respiratory quotient
SNA sympathetic nerve activity
SNS sympathetic nervous system
TG triglycerides
TKO triple adrenoceptor-deficient mice
VGX vagotomized
VMH ventromedial hypothalamic nucleus of the hypothalamus
WAT white adipose tissue
WT wild type
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Figure 1.
Effect of a 7-day ICV MCH (10 µg/day) infusion on cumulative ( A) food intake, ( B) body
weight gain, ( C) food efficiency, ( D) fat mass gain, ( E) non–fat mass gain, and ( F) RQ.
Values are mean ± standard error of the mean of 7–8 animals per group. * P < .05 and ** P
< .01 vs controls.
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Figure 2.
Effect of a 7-day ICV MCH (10 µg/day) infusion on ( A) different fat pad weights; ( B)
isoproterenol-stimulated lipolysis; ( C) histology of WAT; ( D) WAT enzymatic activity of
FAS; ( E) epididymal WAT protein levels of FAS, LPL, CPT-1, uncoupling protein-1
(UCP-1), peroxisome proliferator-activated receptor gamma co-activator-1-α  (PGC1α),
HSL, pHSL, and ACCα ; and ( F) WAT protein levels of CIDEA, JNK1, pJNK1, and the
ratio of pJNK1/JNK1. Protein β-actin levels were used to normalize protein levels. Values
are mean ± standard error of the mean of 7–8 animals per group. * P < .05, ** P < .01; and
*** P < .001 vs controls.
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Figure 3.
Effect of a 7-day ICV MCH (10 µg/day) infusion on ( A) hepatic TG content represented by
oil red ( left) and total TG content ( right); ( B) FFA; ( C) messenger RNA (mRNA) expression
of ACCα , FAS, SCD-1, microsomal TG transfer protein (MTP), low-density lipoprotein
receptor (LDLR), farnesoid X receptor (FXR), scavenger receptor class B type 1 (Scarb1),
liver receptor homolog 1 (LRH1), and SREBP1; ( D) protein levels of pAMPK, AMPKα1,
AMPKα2, pACC, ACCα , FAS, and LPL; ( E) hepatic LPL activity; and ( F) protein levels of
JNK1, pJNK1, and the ratio of pJNK1/JNK1. Data are presented as values normalized to
18S, which was used as a housekeeping gene. Protein levels are relative to controls and β-
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actin, which was used to normalize protein levels. Values are mean ± standard error of the
mean of 7–8 animals per group. * P < .05, ** P < .01, and *** P < .001 vs controls.
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Figure 4.
( A) Effect of a 7-day ICV MCH (10 µg/day) infusion on epididymal WAT messenger RNA
(mRNA) expression of β1-AR, β2-AR, and β3-AR. ( B) Effect of ICV administration of
MCH on SNA subserving epididymal WAT in anesthetized rats. Effect of a 7-day ICV
MCH (2.5 µg/day) infusion on ( C) cumulative food intake and body weight gain; ( D) WAT
protein levels of pAMPK, pACC, ACCα , and FAS in WT; ( E) TKO mice; and ( F) hepatic
TG content in WT and TKO mice. Values are mean ± standard error of the mean of 6
animals per group. * P < .05 and *** P < .001 vs controls.
Imbernon et al. Page 17
Gastroenterology. Author manuscript; available in PMC 2013 September 01.
Figure 5.
Effect of a 7-day ICV MCH (10 µg/day) infusion on ( A) hepatic TG content; ( B) serum
FFA; ( C) hepatic FFA; ( D) oil red staining; ( E) hepatic protein levels of pAMPK, pACC,
ACCα , LPL, and the ratio of pJNK1/JNK1; and the ( F) hepatic LPL activity in sham-
operated rats and VGX rats. β-actin was used to normalize protein levels. Values are mean ±
standard error of the mean of 6–8 animals per group. * P < .05 and ** P < .01 vs controls.
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Figure 6.
Effect of a 7-day ICV MCH (2.5 µg/day) infusion on ( A) cumulative food intake; ( B) body
weight gain; ( C) serum FFA levels in WT and JNK1 KO mice; and ( D) liver protein levels
of pAMPK, pACC, LPL, ACCα , AMPKα1, and AMPKα2 in JNK1 KO mice. Effect of a 6-
day ICV MCH (2.5 µg/day) infusion + IP SP600125 (JNK inhibitor) treatment on ( E) serum
FFA and ( F) liver protein levels of pAMPK, AMPKα1, AMPKα2, and LPL. β-actin was
used to normalize protein levels. Values are mean ± standard error of the mean of 6–8
animals per group. * P < .05 and ** P < .01 vs controls.
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Figure 7.
( A) Localization studies of microinjection sites, showing the immunofluorescence with anti-
GFP antibody in the ARC ( upper panel) and the immunohistochemistry of MCH-R in rats
treated with a GFP- or MCH-R–expressing adenovirus in the ARC ( lower panel). ( B) Body
weight change and cumulative food intake and ( C) protein level profiles in liver of rats
treated stereotaxically with a GFP- ( orange) or MCH-R-expressing adenovirus ( blue) in the
ARC. ( B) Body weight change and cumulative food intake and ( C) protein level profiles in
liver after a 7-day infusion of saline ( white) orMCH (6 µg/day) ( black) specifically into the
ARC. ( D) Localization studies of microinjection, showing the immunofluorescence with
anti-GFP antibody in the LHA ( upper panel) and the immunohistochemistry of MCH-R in
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rats treated with a GFP- or MCH-R–expressing adenovirus in the LHA ( lower panel). ( E)
Body weight change and cumulative food intake and ( F) protein level profiles in liver of rats
treated stereotaxically with a GFP- ( orange) or MCH-R–expressing adenovirus ( blue) in the
LHA. ( E) Body weight change and cumulative food intake and ( F) protein level profiles in
liver after a 7-day infusion of saline ( white) or MCH (6 µg/day) ( black) specifically into the
LHA. β-actin was used to normalize protein levels. Values are mean ± standard error of the
mean of 7–8 animals per group. * P < .05, ** P < .01, and *** P < .001 vs controls.
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